At the event, independent investigators presented poster, "Therapeutic Ultrafiltration to Treat Symptomatic Pediatric Heart Failure," which explored the use of ultrafiltration in a pediatric patient with chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload. The study was designed to evaluate its feasibility, safety, and clinical impact when diuretics and medical management did not prevent hospital readmissions.

"The case presented on the poster reinforces the growing body of evidence supporting precision ultrafiltration as an important tool in managing fluid overload in complex pediatric cardiorenal patients. We continue to work with practitioners to help adopt the Aquadex SmartFlow® pediatric indication and these types of presentations are supportive of our ongoing work toward establishing a standard of care for these patients," said Nuwellis' CEO John Erb. "The use of Aquadex in the case study not only indicates safe and effective fluid management, but also improving clinical status pre operative and improving outcomes post cardiac transplant. The scientific dialogue on the importance and impact of fluid management in the pediatric setting was an important topic discussed at ISHLT."

Nuwellis' Aquadex ultrafiltration therapy is designed to provide controlled, precise fluid removal for patients with fluid overload when diuretics are insufficient, supporting improved clinical management in heart failure and related conditions. It is indicated for continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

ISHLT is a leading global forum that brings together clinicians and researchers focused on advanced heart and lung disease, transplantation, and mechanical circulatory support, highlighting cutting-edge science and innovation in the field. Poster presentations at ISHLT provide an important opportunity for clinicians and researchers to share emerging data and engage in scientific exchange with the global transplant and heart failure community.